Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07490262 for Hepatocellular Carcinoma (HCC) is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. Phase 2, Phase 3 680 Randomized Open-Label Combination Therapy
Clinical Trial NCT07490262 is designed to study Treatment for Hepatocellular Carcinoma (HCC). This Phase 2 Phase 3 interventional study is not yet recruiting. Enrollment is planned to begin on March 31, 2026 until the study accrues 680 participants. Led by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD., this study is expected to complete by December 31, 2030. The latest data from ClinicalTrials.gov was last updated on March 24, 2026.
Brief Summary
This study is a randomized, controlled, open-label, multicenter, seamless Phase II/III trial designed to evaluate the efficacy and safety of the combination regimen of IBI310 and sintilimab in participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who are: (1) treatment-naive to systemic therapy; and (2) either unsuitable for curative-intent surgical resection or local therapy, or have experi...Show More
Official Title
A Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy as First-line Treatment in Previously Untreated Patients With Unresectable or Metastatic Hepatocellular Carcinoma
Conditions
Hepatocellular Carcinoma (HCC)Other Study IDs
- CIBI310C302
NCT ID Number
Start Date (Actual)
2026-03-31
Last Update Posted
2026-03-24
Completion Date (Estimated)
2030-12-31
Enrollment (Estimated)
680
Study Type
Interventional
PHASE
Phase 2
Phase 3
Phase 3
Status
Not yet recruiting
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
Active ComparatorControl Group Sintilimab+ Bevacizumab | Bevacizumab 15 mg/kg intravenous infusion, administered on Day 1 of each 3-week treatment cycle Sintilimab 200 mg intravenous infusion, administered on Day 1 of each 3-week treatment cycle |
ExperimentalTreatment Group2 Sintilimab+ IBI310+Bevacizumab | Bevacizumab 15 mg/kg intravenous infusion, administered on Day 1 of each 3-week treatment cycle IBI310 1 mg/kg intravenous infusion, administered on Day 1 of each 6-week treatment cycle Sintilimab 200 mg intravenous infusion, administered on Day 1 of each 3-week treatment cycle |
ExperimentalTreatment Group3 Sintilimab+ IBI310+Oxaliplatin+Capecitabine | Capecitabine 1000 mg/m² orally, administered on Days 1-14 of each 3-week treatment cycle, maximum 4 cycles. Oxaliplatin 85 mg/m² intravenous infusion, administered on Day 1 of each 3-week treatment cycle, maximum 4 cycles. IBI310 1 mg/kg intravenous infusion, administered on Day 1 of each 6-week treatment cycle Sintilimab 200 mg intravenous infusion, administered on Day 1 of each 3-week treatment cycle |
ExperimentalTreatment Group1 Sintilimab+ IBI310+Bevacizumab+Oxaliplatin+Capecitabine | Bevacizumab 15 mg/kg intravenous infusion, administered on Day 1 of each 3-week treatment cycle Capecitabine 1000 mg/m² orally, administered on Days 1-14 of each 3-week treatment cycle, maximum 4 cycles. Oxaliplatin 85 mg/m² intravenous infusion, administered on Day 1 of each 3-week treatment cycle, maximum 4 cycles. IBI310 1 mg/kg intravenous infusion, administered on Day 1 of each 6-week treatment cycle Sintilimab 200 mg intravenous infusion, administered on Day 1 of each 3-week treatment cycle |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Phase II: ORR （Objective Response Rate） assessed by investigator per RECIST 1.1. | up to 2 years | |
Phase II: PFS（Progression-Free Survival） assessed by investigator per RECIST 1.1. | up to 2 years | |
Phase II: AEs（Adverse Event） | up to 2 years | |
Phase II: TRAES（Treatment Emergent Adverse Event） | up to 2 years | |
Phase II: SAEs（Serious Adverse Event） | up to 2 years | |
Phase III: OS（Overall Survival） | up to 2 years | |
Phase III: PFS（Progression-Free Survival）assessed by the Independent Radiologic Review Committee (IRRC) per RECIST 1.1. | up to 2 years |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Phase II: OS | up to 2 years | |
Phase II: Incidence and characteristics of ADA&Nab. | up to 2 years | |
Phase II: DoR (Duration of Response ) | up to 2 years | |
Phase II: DCR (Disease Control Rate ) | up to 2 years | |
Phase II: TTR (Time to Response ) | up to 2 years | |
Phase II:Cmax (maximum plasma concentration) | One of the Pharmacokinetics parameters | up to 2 years |
Phase II:Tmax (time to reach maximum concentration) | One of the Pharmacokinetics parameters | up to 2 years |
Phase II: AUC (time curve) | One of the Pharmacokinetics parameters | up to 2 years |
PhaseIII: ORR （Objective Response Rate）assessed by IRRC according to RECIST1.1. | up to 2 years | |
PhaseIII: DoR （Duration of Response）assessed by IRRC according to RECIST1.1. | up to 2 years | |
PhaseIII: DCR （Time to Response）assessed by IRRC according to RECIST1.1. | up to 2 years | |
PhaseIII: TTR（Time to Response） assessed by IRRC according to RECIST1.1. | up to 2 years | |
PhaseIII: ORR （Objective Response Rate）assessed by the investigator according to RECIST1.1. | up to 2 years | |
PhaseIII: PFS （Progression-Free Survival）assessed by the investigator according to RECIST1.1. | up to 2 years | |
PhaseIII: DoR （Duration of Response）assessed by the investigator according to RECIST1.1. | up to 2 years | |
PhaseIII: DCR（Time to Response） assessed by the investigator according to RECIST1.1. | up to 2 years | |
PhaseIII: TTR (Time to Response) assessed by the investigator according to RECIST1.1. | up to 2 years | |
Phase III: ORR （Objective Response Rate）assessed by IRRC according to mRECIST. | up to 2 years | |
Phase III: PFS（Progression-Free Survival） assessed by IRRC according to mRECIST. | up to 2 years | |
Phase III: DoR（Duration of Response） assessed by IRRC according to mRECIST. | up to 2 years | |
Phase III: DCR（Disease Control Rate） assessed by IRRC according to mRECIST. | up to 2 years | |
Phase III: TTR（Time to Response） assessed by IRRC according to mRECIST. | up to 2 years | |
Phase III: incidence rate of AEs（Adverse Event） | up to 2 years | |
Phase III: incidence rate of TEAEs（Treatment Emergent Adverse Event） | up to 2 years | |
Phase III: incidence rate of SAEs（Serious Adverse Event） | up to 2 years | |
Phase III: Cmax | One of the Pharmacokinetics parameters | up to 2 years |
Phase III: CL(Clearance) | One of the Pharmacokinetics parameters | up to 2 years |
Phase III: t1/2 (Half-Life) | One of the Pharmacokinetics parameters | up to 2 years |
Phase III: Volume | One of the Pharmacokinetics parameters | up to 2 years |
Phase III: AUC (Area Under the Curve) | One of the Pharmacokinetics parameters | up to 2 years |
Phase III: Incidence and characteristics of ADA&Nab. | up to 2 years | |
Phase II: Volume（PK） | One of the Pharmacokinetics parameters | up to 2 years |
Phase II: t1/2 (Half-Life) | One of the Pharmacokinetics parameters | up to 2 years |
phase III: score of (European Organization for Research and Treatment of Cancer, EORTC）EORTC QLQ-C30 | up to 2 years | |
phase III: score of (Eropean Organization for Research and Treatment of Cancer, EORTC）EORTC QLQ-HCC18 | up to 2 years | |
Phase II: CL (Clearance) | One of the Pharmacokinetics parameters | up to 2 years |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
- Histologically or cytologically confirmed hepatocellular carcinoma (HCC).
- Age ≥18 years and ≤75 years.
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.
- Barcelona Clinic Liver Cancer (BCLC) staging of Stage C, or Stage B that is unsuitable for curative-intent surgery and/or locoregional therapy.
- No prior systemic antineoplastic therapy for HCC before first dose.
- At screening, per RECIST 1.1, there must be at least one measurable lesion that has not undergone local therapy, or a measurable lesion that has clearly progressed following local therapy (per RECIST 1.1).
- Child-Pugh score ≤7.
- Adequate organ and bone marrow function.
- Expected survival ≥12 weeks at the time of treatment initiation.
- Female participants of childbearing potential, or male participants whose sexual partners are of childbearing potential, must use effective contraception throughout the treatment period and for 15 months after the last dose of oxaliplatin (for females) / 12 months after the last dose of oxaliplatin (for males), or for 6 months after the last dose of any other investigational drug-whichever period ends later.
- Signed written informed consent form, and ability to comply with scheduled visits and all protocol-specified procedures.
- Histologically or cytologically confirmed diagnosis of fibrolamellar hepatocellular carcinoma (HCC), sarcomatoid HCC, cholangiocarcinoma, or other mixed hepatic malignancies containing these components.
- History of hepatic encephalopathy or prior liver transplantation.
- Clinically symptomatic pleural effusion, ascites, or pericardial effusion requiring therapeutic drainage; participants with only minimal (radiologically detected), asymptomatic effusions may be enrolled.
- Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection:
- Known central nervous system (CNS) metastases or symptomatic spinal cord compression.
- Esophageal or gastric variceal bleeding due to portal hypertension within the past 6 months; Grade 3 (G3) esophageal/gastric varices documented by endoscopy within 3 months prior to first dose; or evidence of portal hypertension.
- Life-threatening hemorrhagic event within the past 3 months, including but not limited to events requiring blood transfusion, surgical or local intervention, or ongoing pharmacologic hemostatic therapy.
- Metastatic lesions invading major vessels, airways, or the mediastinum with clinically significant bleeding risk.
- Arterial or venous thromboembolic event within the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident (stroke), transient ischemic attack (TIA), pulmonary embolism, deep vein thrombosis, or other severe thromboembolic conditions.
- Portal vein tumor thrombus (PVTT) involving both the main portal vein and left/right branch; PVTT extending into the superior mesenteric vein; or PVTT involving the inferior vena cava.
- Use of aspirin (>325 mg/day) or other known platelet-function-inhibiting agents (e.g., dipyridamole or clopidogrel) for therapeutic purposes within 10 days prior to randomization. Prophylactic use of anticoagulants is permitted.
- Uncontrolled hypertension: systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg despite optimal medical management; history of hypertensive crisis or hypertensive encephalopathy.
- Persistent treatment-related toxicities from prior anticancer therapy not resolved to Grade 0 or Grade 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 at the time of randomization.
- Symptomatic congestive heart failure (New York Heart Association \[NYHA\] Class II-IV); symptomatic or inadequately controlled arrhythmias; history of congenital long QT syndrome; or baseline corrected QT interval (QTcF, calculated using Fridericia's formula) >500 ms.
- Severe bleeding diathesis or coagulopathy; or current thrombolytic therapy.
- History of gastrointestinal perforation and/or fistula within the past 6 months; unresolved intestinal obstruction (including incomplete obstruction requiring parenteral nutrition); extensive bowel resection (e.g., partial colectomy or extensive small bowel resection leading to chronic diarrhea); Crohn's disease; ulcerative colitis; or chronic diarrhea of prolonged duration.
- Prior radiotherapy within 3 weeks before randomization.
- Clinically significant pre-existing pulmonary disease.
- Active tuberculosis (TB), currently receiving anti-TB therapy, or having completed anti-TB therapy within the past year.
- Known human immunodeficiency virus (HIV) infection (positive HIV-1/2 antibody test).
- Active or inadequately controlled severe infection.
- Known or suspected active autoimmune disease, or history of active autoimmune disease within the past 2 years.
- Systemic immunosuppressive therapy within 2 weeks prior to randomization.
- Receipt of live attenuated vaccines within 4 weeks prior to randomization, or planned administration during the study.
- Major surgery (e.g., craniotomy, thoracotomy, laparotomy) or presence of unhealed wounds, ulcers, or fractures within 4 weeks prior to randomization.
- Local therapy for HCC within 4 weeks prior to first dose.
- Use of Traditional Chinese Medicine (TCM) with antitumor indications, or immunomodulatory agents (e.g., thymosin, interferons, interleukins), within 2 weeks prior to first dose.
- Uncontrolled or uncorrectable metabolic disorders, non-malignant organ dysfunction, systemic illness, or cancer-related paraneoplastic syndromes posing substantial medical risk or introducing uncertainty in survival assessment - as determined by the investigator; or any other condition deemed unsuitable for enrollment by the investigator.
- Diagnosis of another primary malignancy within 5 years prior to randomization.
- Prior treatment with any anti-PD-1, anti-PD-L1/L2, anti-CTLA-4 antibodies, or other immune checkpoint inhibitors.
- Known hypersensitivity to any active ingredient or excipient of the investigational product; or history of severe allergic reaction (e.g., anaphylaxis) to other monoclonal antibodies.
- Receipt of treatment in another interventional clinical trial within 4 weeks prior to randomization.
- Female participants who are pregnant or breastfeeding.
- Any other acute or chronic medical condition, psychiatric disorder, or clinically significant laboratory abnormality that, in the Investigator's judgment: increases the risks associated with participation in the study or administration of the investigational product; or may interfere with the interpretation of study results - rendering the participant unsuitable for enrollment.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Study Central Contact
Contact: Haiyun Zuo, 021-31852088, [email protected]
1 Study Locations in 1 Countries
Anhui
The First Affiliated Hosptial of USTC, Hefei, Anhui, 230001, China
Lianxin Liu, Contact, 0551-62283477, [email protected]